Transoral robotic surgery and a paradigm shift in the management of oropharyngeal squamous cell carcinoma

Journal of Robotic Surgery

Volumn 4, Issue 2, 2010, Pages 79-86

  Quon, Harry ^a,b,c,d   O'Malley, Bert W ^a,b,c   Weinstein, Gregory S ^a,b,c  

^a Department of Radiation Oncology ^*  (United States)

^b UNIVERSITY OF PENNSYLVANIA   (United States)

^c UNIVERSITY OF PENNSYLVANIA   (United States)

^d HOSPITAL OF THE UNIVERSITY OF PENNSYLVANIA   (United States)

Author keywords

Concurrent chemotherapy; Oropharynx carcinoma; Radiotherapy; Review; Risk stratification; Transoral robotic surgery; Treatment paradigm; Treatment related swallowing complications

Indexed keywords

CHEMOTHERAPY; ROBOTIC SURGERY;

CONCURRENT CHEMOTHERAPY; OROPHARYNGEAL CARCINOMATA; OROPHARYNX; OROPHARYNX CARCINOMA; PARADIGM SHIFTS; RISK STRATIFICATION; ROBOTICS SURGERY; TRANSORAL ROBOTIC SURGERY; TREATMENT PARADIGM; TREATMENT-RELATED SWALLOWING COMPLICATION;

RADIOTHERAPY;

EID: 77955431487     PISSN: 18632483     EISSN: None     Source Type: Journal    
DOI: 10.1007/s11701-010-0194-y     Document Type: Review

References (54)

1. Langendijk JA, Doornaert P, Verdonck-de Leeuw IM, Leemans CR, Aaronson NK, Slotman BJ (2008) Impact of late treatment-related toxicity on quality of life among patients with head and neck cancer treated with radiotherapy. J Clin Oncol 26(22): 3770-3776.
2. Marchetta FC (1976) Function and appearance following surgery for intraoral cancer. Clin Plast Surg 3(3): 471-479.
3. Withers EH, Franklin JD, Madden JJ Jr, Lynch JB (1979) Pectoralis major musculocutaneous flap: a new flap in head and neck reconstruction. Am J Surg 138(4): 537-543.
4. Maccomb WS, Fletcher GH (1957) Planned combination of surgery and radiation in treatment of advanced primary head and neck cancers. Am J Roentgenol, Radium Therapy, Nucl Med 77(3): 397-414.
5. Jesse RH, Lindberg RD (1975) The efficacy of combining radiation therapy with a surgical procedure in patients with cervical metastasis from squamous cancer of the oropharynx and hypopharynx. Cancer 35(4): 1163-1166.
6. Jesse RH, Fletcher GH (1977) Treatment of the neck in patients with squamous cell carcinoma of the head and neck. Cancer 39(2 Suppl): 868-872.
7. Fletcher GH, Evers WT (1970) Radiotherapeutic management of surgical recurrences and postoperative residuals in tumors of the head and neck. Radiology 95(1): 185-188.
8. Goffinet DR, Gilbert EH, Weller SA, Bagshaw MA (1975) Irradiation of clinically uninvolved cervical lymph nodes. Can J Otolaryngol 4(5): 927-933.
9. Weller SA, Goffinet DR, Goode RL, Bagshaw MA (1976) Carcinoma of the oropharynx. Results of megavoltage radiation therapy in 305 patients. Ajr 126(2): 236-247.
10. Spiro RH, Gerold FP, Strong EW (1981) Mandibular "swing" approach for oral and oropharyngeal tumors. Head Neck Surg 3(5): 371-378.
11. Kaplan R, Million RR, Cassisi NJ (1977) Carcinoma of the tonsil: results of radical irradiation with surgery reserved for radiation failure. Laryngoscope 87(4Pt1): 600-607.
12. Strong MS, Vaughan CW, Kayne HL, Aral IM, Ucmakli A, Feldman M et al (1978) A randomized trial of preoperative radiotherapy in cancer of the oropharynx and hypopharynx. Am J Surg 136(4): 494-500.
13. Quenelle DJ, Crissman JD, Shumrick DA (1979) Tonsil carcinoma-treatment results. Laryngoscope 89(11): 1842-1846.
14. Gullane PJ, Jabbour JM, Conley JJ, Nealon TF Jr (1979) Correlation of pharyngeal fistulization with preoperative radiotherapy, reduced serum albumen, and dietary obstruction. Otolaryngol Head Neck Surg 87(3): 311-317.
15. Tupchong L, Scott CB, Blitzer PH, Marcial VA, Lowry LD, Jacobs JR, et al. (1991) Randomized study of preoperative versus postoperative radiation therapy in advanced head and neck carcinoma: long-term follow-up of RTOG study 73-03. Int J Radiat Oncol Biol Phys 20(1): 21-28.
16. The Department of Veterans Affairs Laryngeal Cancer Study Group (1991) Induction chemotherapy plus radiation compared with surgery plus radiation in patients with advanced laryngeal cancer. N Engl J Med 324(24): 1685-1690.
17. Withers HR (1985) Biologic basis for altered fractionation schemes. Cancer 55(9 Suppl): 2086-2095.
18. Fu KK, Pajak TF, Trotti A, Jones CU, Spencer SA, Phillips TL et al. (2000) A radiation therapy oncology group (RTOG) phase III randomized study to compare hyperfractionation and two variants of accelerated fractionation to standard fractionation radiotherapy for head and neck squamous cell carcinomas: first report of RTOG 9003. Int J Radiat Oncol Biol Phys 48(1): 7-16.
19. Bourhis J, Overgaard J, Audry H, Ang KK, Saunders M, Bernier J et al (2006) Hyperfractionated or accelerated radiotherapy in head and neck cancer: a meta-analysis. Lancet 368(9538): 843-854.
20. Adelstein DJ, Saxton JP, Rybicki LA, Esclamado RM, Wood BG, Strome M et al (2006) Multiagent concurrent chemoradiotherapy for locoregionally advanced squamous cell head and neck cancer: mature results from a single institution. J Clin Oncol 24(7): 1064-1071.
21. Calais G, Alfonsi M, Bardet E, Sire C, Germain T, Bergerot P et al. (2000) Stage III and IV cancers of the oropharynx: results of a randomized study of Gortec comparing radiotherapy alone with concomitant chemotherapy. Bulletin du Cancer 87 Spec No: 48-53.
22. Brizel DM, Albers ME, Fisher SR, Scher RL, Richtsmeier WJ, Hars V et al (1998) Hyperfractionated irradiation with or without concurrent chemotherapy for locally advanced head and neck cancer. N Engl J Med 338(25): 1798-1804.
23. Bernier J, Domenge C, Ozsahin M, Matuszewska K, Lefebvre JL, Greiner RH et al (2004) Postoperative irradiation with or without concomitant chemotherapy for locally advanced head and neck cancer. N Engl J Med 350(19): 1945-1952.
24. Cooper JS, Pajak TF, Forastiere AA, Jacobs J, Campbell BH, Saxman SB et al (2004) Postoperative concurrent radiotherapy and chemotherapy for high-risk squamous-cell carcinoma of the head and neck. N Engl J Med 350(19): 1937-1944.
25. Pignon JP, le Maitre A, Maillard E, Bourhis J (2009) Meta-analysis of chemotherapy in head and neck cancer (MACH-NC): an update on 93 randomised trials and 17, 346 patients. Radiother Oncol 92(1): 4-14.
26. Posner MR, Hershock DM, Blajman CR, Mickiewicz E, Winquist E, Gorbounova V et al (2007) Cisplatin and fluorouracil alone or with docetaxel in head and neck cancer. N Engl J Med 357(17): 1705-1715.
27. Vermorken JB, Remenar E, van Herpen C, Gorlia T, Mesia R, Degardin M et al (2007) Cisplatin, fluorouracil, and docetaxel in unresectable head and neck cancer. N Engl J Med 357(17): 1695-1704.
28. Hitt R, Grau JJ, Lopez-Pousa A, Berrocal A, Garcia Giron C, Irigoyen A et al. (2009) Final results of a randomized phase III trial comparing induction chemotherapy with cisplatin/5-FU or docetaxel/cisplatin/5-FU follow by chemoradiotherapy (CRT) versus CRT alone as first-line treatment of unresectable locally advanced head and neck cancer (LAHNC). ASCO Meeting Abstracts. 5/20; 27(15S): 6009.
29. Bonner JA, Harari PM, Giralt J, Azarnia N, Shin DM, Cohen RB et al (2006) Radiotherapy plus cetuximab for squamous-cell carcinoma of the head and neck. N Engl J Med 354(6): 567-578.
30. Bonner JA, Harari PM, Giralt J, Cohen RB, Jones CU, Sur RK et al (2010) Radiotherapy plus cetuximab for locoregionally advanced head and neck cancer: 5-year survival data from a phase 3 randomised trial, and relation between cetuximab-induced rash and survival. Lancet Oncol 11(1): 21-28.
31. Rischin D, Hicks RJ, Fisher R, Binns D, Corry J, Porceddu S et al. (2006) Prognostic significance of [18F]-misonidazole positron emission tomography-detected tumor hypoxia in patients with advanced head and neck cancer randomly assigned to chemoradiation with or without tirapazamine: a substudy of Trans-Tasman Radiation Oncology Group Study 98. 02. J Clin Oncol 24(13): 2098-2104.
32. Overgaard J, Horsman MR (1996) Modification of hypoxia-induced radioresistance in tumors by the use of oxygen and sensitizers. Semin Radiat Oncol 6(1): 10-21.
33. Le QT, Taira A, Budenz S, Jo Dorie M, Goffinet DR, Fee WE et al (2006) Mature results from a randomized Phase II trial of cisplatin plus 5-fluorouracil and radiotherapy with or without tirapazamine in patients with resectable Stage IV head and neck squamous cell carcinomas. Cancer 106(9): 1940-1949.
34. Rischin D, Peters L, Fisher R, Macann A, Denham J, Poulsen M et al. (2005) Tirapazamine, cisplatin, and radiation versus fluorouracil, cisplatin, and radiation in patients with locally advanced head and neck cancer: a randomized phase II trial of the Trans-tasman radiation oncology group (TROG 98. 02). J Clin Oncol 23(1): 79-87.
35. Caudell JJ, Schaner PE, Meredith RF, Locher JL, Nabell LM, Carroll WR et al. (2009) Factors associated with long-term dysphagia after definitive radiotherapy for locally advanced head-and-neck cancer. Int J Radiat Oncol Biol Phys 73(2): 410-415.
36. Langendijk JA, Doornaert P, Rietveld DH, Verdonck-de Leeuw IM, Leemans CR, Slotman BJ (2009) A predictive model for swallowing dysfunction after curative radiotherapy in head and neck cancer. Radiother Oncol 90(2): 189-195.
37. Machtay M, Moughan J, Trotti A, Garden AS, Weber RS, Cooper JS et al (2008) Factors associated with severe late toxicity after concurrent chemoradiation for locally advanced head and neck cancer: an RTOG analysis. J Clin Oncol 26(21): 3582-3589.
38. Feng FY, Kim HM, Lyden TH, Haxer MJ, Feng M, Worden FP et al. (2007) Intensity-modulated radiotherapy of head and neck cancer aiming to reduce dysphagia: early dose-effect relationships for the swallowing structures. Int J Radiat Oncol Biol Phys 68(5): 1289-1298.
39. http://www. nccn. org/professionals/physician_gls/f_guidelines. asp.
40. Levendag PC, Teguh DN, Voet P, van der Est H, Noever I, de Kruijf WJ et al (2007) Dysphagia disorders in patients with cancer of the oropharynx are significantly affected by the radiation therapy dose to the superior and middle constrictor muscle: a dose-effect relationship. Radiother Oncol 85(1): 64-73.
41. Gillison ML, Harris J, Westra W, Chung C, Jordan R, Rosenthal D et al. (2009) Survival outcomes by tumor human papillomavirus (HPV) status in stage III-IV oropharyngeal cancer (OPC) in RTOG 0129. J Clin Oncol (Meeting Abstracts). 27(15S): 6003.
42. Fakhry C, Westra WH, Li S, Cmelak A, Ridge JA, Pinto H et al (2008) Improved survival of patients with human papillomavirus-positive head and neck squamous cell carcinoma in a prospective clinical trial. J Natl Cancer Inst 100(4): 261-269.
43. Licitra L, Perrone F, Bossi P, Suardi S, Mariani L, Artusi R et al (2006) High-risk human papillomavirus affects prognosis in patients with surgically treated oropharyngeal squamous cell carcinoma. J Clin Oncol 24(36): 5630-5636.
44. Gillison ML, Koch WM, Capone RB, Spafford M, Westra WH, Wu L et al (2000) Evidence for a causal association between human papillomavirus and a subset of head and neck cancers. J Natl Cancer Inst 92(9): 709-720.
45. Dosoretz A, Dutta PR, Lin A, Alonso-Basanta M, BarAd V, Both S et al. (2010) Long-term percutaneous gastrostomy tube dependence rates in patients treated with intensity-modulated radiotherapy for oropharyngeal cancer: the university of pennsylvania experience. AHNS/ASCO/ASTRO Multi-Disciplinary Head and Neck Cancer Symposium; Chandler, Arizona, poster 14, p 49.
46. Moore EJ, Olsen KD, Kasperbauer JL (2009) Transoral robotic surgery for oropharyngeal squamous cell carcinoma: a prospective study of feasibility and functional outcomes. Laryngoscope 119(11): 2156-2164.
47. Grant DG, Hinni ML, Salassa JR, Perry WC, Hayden RE, Casler JD (2009) Oropharyngeal cancer: a case for single modality treatment with transoral laser microsurgery. Arch Otolaryngol Head Neck Surg 135(12): 1225-1230.
48. Steiner W, Fierek O, Ambrosch P, Hommerich CP, Kron M (2003) Transoral laser microsurgery for squamous cell carcinoma of the base of the tongue. Arch Otolaryngol Head Neck Surg 129(1): 36-43.
49. Rich JT, Milov S, Lewis JS Jr, Thorstad WL, Adkins DR, Haughey BH (2009) Transoral laser microsurgery (TLM) ± adjuvant therapy for advanced stage oropharyngeal cancer: outcomes and prognostic factors. Laryngoscope 119(9): 1709-1719.
50. Laccourreye O, Hans S, Menard M, Garcia D, Brasnu D, Holsinger FC (2005) Transoral lateral oropharyngectomy for squamous cell carcinoma of the tonsillar region: II. An analysis of the incidence, related variables, and consequences of local recurrence. Arch Otolaryngol Head Neck Surg 131(7): 592-599.
51. Worden FP, Hooton J, Lee J, Eisbruch A, Wolf GT, Prince M et al. (2009) Association of tobacco (T) use with risk of distant metastases (DM), tumor recurrence, and death in patients (pts) with HPV-positive (+) squamous cell cancer of the oropharynx (SCCOP). J Clin Oncol (Meeting Abstracts). 27(15S): 6001.
52. Fischer CA, Zlobec I, Green E, Probst S, Storck C, Lugli A et al (2009) Is the improved prognosis of p16 positive oropharyngeal squamous cell carcinoma dependent of the treatment modality? Int J Cancer 126(5): 1256-1262.
53. Weinberger PM, Yu Z, Haffty BG, Kowalski D, Harigopal M, Brandsma J et al (2006) Molecular classification identifies a subset of human papillomavirus-associated oropharyngeal cancers with favorable prognosis. J Clin Oncol 24(5): 736-747.
54. Lassen P, Eriksen JG, Hamilton-Dutoit S, Tramm T, Alsner J, Overgaard J (2010) HPV-associated p16-expression and response to hypoxic modification of radiotherapy in head and neck cancer. Radiother Oncol 94(1): 30-35.